In disease states, GLP‐1 receptor mimetics reduce hyperlipidaemia, liver fibrosis and inflammation in non‐alcoholic fatty liver disease (NAFLD) (Armstrong et al., 2016; Newsome et al., 2020) as well as liver fat content in type 2 diabetes (Petit et al., 2017). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.